Update on Clinical Trials in Systemic Lupus Erythematosus

Sonali Narain; Richard Furie

Disclosures

Curr Opin Rheumatol. 2016;28(5):477-487. 

In This Article

Targeting B Cells

B-cell targeted therapies have dominated drug development endeavors owing to the role of B lymphocytes in the pathogenesis of SLE and the regulatory approval of belimumab. Although various strategies have been conceived, the general tactic has been to affect qualitative and/or quantitative changes in B cells.[2] Key trials are illustrated in Table 1.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....